Pharmaceutical Suppositories Market Report 2025

The pharmaceutical suppositories market size has grown strongly in recent years. It will grow from $1.68 billion in 2024 to $1.79 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increased healthcare expenditure, new regulatory approvals for marketing suppositories, government initiatives, the rise in the prevalence of constipation, and the increasing prevalence of diseases.

The pharmaceutical suppositories market size is expected to see strong growth in the next few years. It will grow to $2.33 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to an increase in the prevalence of kidney damage or failure and an increase in the prevalence of hemorrhoids. Major trends in the forecast period include strategic partnerships, technological advancements, product innovation, and a focus on patient convenience and adherence.

The rising prevalence of diseases is expected to drive the growth of the pharmaceutical suppositories market in the coming years. This increase in disease prevalence can be attributed to factors such as geology, climate, and insect transmission of pathogens. Pharmaceutical suppositories serve as an effective treatment option for the growing number of patients suffering from various ailments. These suppositories are a drug delivery method that involves inserting a small, cylindrical, or conical device into the body, typically through the rectum, where it dissolves or melts to release the medication and treat the condition. For example, a United Nations article indicates that by 2030, chronic diseases are projected to account for 70% of all global fatalities, with nearly 60% of all deaths expected to result from chronic illnesses. Thus, the rising prevalence of diseases is significantly boosting the pharmaceutical suppositories market.

The growing size of the aging population is anticipated to contribute significantly to the expansion of the pharmaceutical suppositories market in the future. A substantial portion of the elderly population is bedridden, making them more susceptible to various health issues such as constipation and urinary tract infections. Suppositories play a crucial role in providing adequate nursing care for those who are confined to bed, thereby driving market growth. For instance, the World Health Organization projects that by 2030, one in six individuals worldwide will be aged 60 years or older. By 2050, the global population of people aged 60 and above is expected to double, reaching 2.1 billion. Additionally, the number of individuals aged 80 years and older is projected to triple by 2050, totaling 426 million. Consequently, the aging population is expected to bolster the demand for pharmaceutical suppositories, fueling market growth.

Technological advancements are becoming a prominent trend in the pharmaceutical suppositories market. Leading companies in this sector are leveraging advanced technologies to maintain their competitive edge. For example, in August 2023, Zydus Lifesciences, a pharmaceutical company based in India, received approval from the US FDA for Indomethacin suppositories, which hold a Competitive Generic Therapy (CGT) designation. This designation facilitates the accelerated development of generic drugs facing limited competition, thereby making treatments more affordable. The advanced formulation of these suppositories ensures effective delivery and absorption. Zydus was also granted a 180-day exclusivity period, promoting innovation within the industry. Comprehensive testing confirmed that the product meets high standards of quality, safety, and efficacy.

Product innovation is emerging as a significant trend in the pharmaceutical suppositories market. Leading companies in this sector are developing novel products to enhance their market presence. For example, in 2024, Aprecia Pharmaceuticals, a US-based company specializing in 3D printing technology, introduced 3D-printed suppositories designed for personalized medicine. These suppositories can be customized to meet individual patient needs, allowing for precise dosage control and tailored drug release profiles. This innovation highlights the growing emphasis on personalized and precision medicine within the pharmaceutical industry, where treatments are specifically designed to address the unique requirements of each patient. By tailoring treatments to individual genetic profiles, personalized medicine enhances effectiveness and minimizes adverse reactions. Additionally, this approach can lower healthcare costs and improve disease management through early diagnosis and continuous monitoring.

In April 2023, Merck & Co., Inc., a pharmaceutical company headquartered in the United States, completed the acquisition of Prometheus Biosciences for a total consideration of $10.8 billion. This strategic acquisition positions Merck to participate in the Phase 2 trial for treatments targeting ulcerative colitis and Crohn’s disease through Prometheus's monoclonal antibody therapy delivered via suppositories. Prometheus Biosciences, a U.S.-based biotechnology company, specializes in developing precision therapies for immune-mediated diseases, leveraging innovative suppository-based approaches.

Major companies operating in the pharmaceutical suppositories market include Bayer AG, Pfizer Inc, Novartis International Ag, Sanofi S.A., Intas Pharmaceuticals Ltd,Unither Pharmaceuticals, Cosette Pharmaceuticals, Inc, Aenova Holding GmbH, Delpharm, Bliss GVS Pharma Ltd, JoinHub Pharma, Sun Pharmaceutical Industries Ltd, Cipla Ltd, Divis Laboratories Ltd, Dr. Reddys Laboratories Ltd, Apollo Hospitals Enterprise Ltd, Torrent Pharmaceuticals Ltd, Amgen, Bristol Myers Squibb, Chiesi Farmaceutici, CSPC Pharmaceutical Group, Esteve Química, Humanwell Healthcare (Group) Co, Jiangsu Hengrui Pharmaceutical, GlaxoSmithKline (GSK), Nordic Pharma Group, Phoenix Pharma Group, DocMorris, Medpex, AstraZeneca, Abbott Laboratories, Mylan, Zentiva, Merck & Co, Teva Pharmaceutical Industries Ltd, AbbVie Inc, Apotex, Gilead Sciences, Roche, EMS Pharma, Biolab Farmaceutica, Boehringer Ingelheim, JRS Pharma, Roquette, Odan Laboratories Ltd, Axantia, Kiara Health (Pty) Ltd, IBD Africa, Menarini Group, Padagis LLC.

North America was the largest region in the pharmaceutical suppositories market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical suppositories market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical suppositories market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

A pharmaceutical suppository is a small, solid medication block designed to be inserted into the vagina or rectum, gradually dissolving at body temperature.

The primary categories of pharmaceutical suppositories include rectal suppositories, vaginal suppositories, urethral suppositories, and others. Rectal suppositories are medication delivery systems inserted into the rectum, utilizing bases such as fatty, water-miscible, and emulsifying bases. These suppositories find application in various healthcare settings, including hospitals, clinics, nursing homes, home care, and other end-users.

The pharmaceutical suppositories market research report is one of a series of new reports that provides pharmaceutical suppositories market statistics, including pharmaceutical suppositories industry global market size, regional shares, competitors with pharmaceutical suppositories market share, detailed pharmaceutical suppositories market segments, market trends, and opportunities, and any further data you may need to thrive in the pharmaceutical suppositories industry. This pharmaceutical suppository market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharmaceutical suppositories market consists of sales of conventional suppositories, in vitro fertilization, and vardenafil. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.